The goal of this clinical research study is to learn if giving pentostatin with alemtuzumab
can help to control T-cell malignancy. The safety of this combination therapy will also be
studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Astex Pharmaceuticals Astex Pharmaceuticals, Inc. Bayer